Dr. Steensma Discusses Iron Chelation Therapy for MDS
Dr. David Steensma, from Dana-Farber Cancer Institute, Discusses Iron Chelation Therapy for MDS
Managing Chronic Myeloid Leukemia Treatment
Certain characteristics of patients with CML can affect therapeutic outcomes.
New Model Helps Guide Treatment Options in CLL
A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.
Dr. Erba Describes Proper Diagnostic Testing of CML
Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML
Dr. Dunleavy Discusses 3 Molecular Subtypes of DLBCL
Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL
Current Trends in the Treatment of Newly Diagnosed Myeloma
A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.
New Directions in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.
Dr. Ansell on Waldenstrom Macroglobulinemia Types
Dr. Stephen Ansell from the Mayo Clinic Describes Waldenström Macroglobulinemia
Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma
Piecing Together the Proper BTK Usage in CLL
Real-World Experience With CAR T Varies From Trials in DLBCL
TAB-Follicular Lymphoma
